Radiopharmaceutical Formulation and Preclinical Testing of ⁶⁸Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial

• Main Authors: Anton A. Hörmann (Author), Maximilian Klingler (Author), Christine Rangger (Author), Christian Mair (Author), Clemens Decristoforo (Author), Christian Uprimny (Author), Irene J. Virgolini (Author), Elisabeth von Guggenberg (Author)
• Format: Book
• Published: MDPI AG, 2021-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The new minigastrin analog DOTA-MGS5 is a promising new candidate for targeting cholecystokinin-2 receptor (CCK2R)-expressing tumors. To enable the clinical translation of PET/CT imaging using ⁶⁸Ga-labeled DOTA-MGS5, different quality and safety aspects need to be considered t...